Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld, Abbisko out-licensed China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback